Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer
Abroad (travel likely)RecruitingPHASE3
Conditions
Pancreatic Cancer, Adult
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin Municipality, China
Contact: Study coordinator (Song Gao, M.D.)
Study leads
Jihui Hao, M.D.
Principal Investigator
Tianjin Medical University Cancer Institute and Hospital
Song Gao, M.D.
Principal Investigator
Tianjin Medical University Cancer Institute and Hospital